Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Phase II Reactions: Glucuronidation01:24

Phase II Reactions: Glucuronidation

Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

`3-Hydroxy-6H,7H-chromeno [3,4-c]chromene-6,7-dione as a Substrate for Studying Glucuronidation, Sulfonation and Lactone Hydrolysis.

Drug metabolism and bioanalysis letters·2026
Same author

Efflux and uptake of androgen sulfates using transporter-overexpressing HEK293 cells and membrane vesicles.

Journal of pharmaceutical sciences·2025
Same author

Genome-wide analyses of neonatal jaundice reveal a marked departure from adult bilirubin metabolism.

Nature communications·2024
Same author

Anthraquinone biocolourant dermocybin is metabolized whereas dermorubin is not in in vitro liver fractions and recombinant metabolic enzymes.

Basic & clinical pharmacology & toxicology·2024
Same author

Human UDP-glucuronosyltransferase 1As catalyze aristolochic acid D O-glucuronidation to form a lesser nephrotoxic glucuronide.

Journal of ethnopharmacology·2024
Same author

Characterization of the glucuronidating pathway of pectolinarigenin, the major active constituent of the Chinese medicine Daji, in humans and its influence on biological activities.

Journal of ethnopharmacology·2023

Related Experiment Video

Updated: Jul 3, 2026

Cost-Efficient Transcriptomic-Based Drug Screening
06:40

Cost-Efficient Transcriptomic-Based Drug Screening

Published on: February 23, 2024

High-throughput screening technologies for drug glucuronidation profiling.

Olga Trubetskoy1, Moshe Finel, Vladimir Trubetskoy

  • 1School of Pharmacy, University of Wisconsin, Madison, Wisconsin, USA.

The Journal of Pharmacy and Pharmacology
|July 23, 2008
PubMed
Summary
This summary is machine-generated.

Developing reliable assays for uridine diphosphoglucuronosyltransferases (UGTs) is crucial for understanding drug metabolism. This review explores high-throughput screening (HTS) advancements and challenges in identifying UGT substrates and inhibitors.

More Related Videos

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

Related Experiment Videos

Last Updated: Jul 3, 2026

Cost-Efficient Transcriptomic-Based Drug Screening
06:40

Cost-Efficient Transcriptomic-Based Drug Screening

Published on: February 23, 2024

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

Area of Science:

  • Biochemistry
  • Pharmacology
  • Enzymology

Background:

  • Glucuronidation, catalyzed by uridine diphosphoglucuronosyltransferases (UGTs), is a key metabolic pathway for many endogenous and exogenous compounds, including therapeutic agents.
  • Understanding UGTs is vital for drug development, predicting drug interactions, and comprehending their clinical and pharmacological relevance.
  • Research on UGT structure, substrate specificity, and inhibition is rapidly evolving.

Purpose of the Study:

  • To review the current status of high-throughput screening (HTS) assays for identifying novel UGT substrates and inhibitors.
  • To highlight advancements and challenges in applying HTS technologies for drug glucuronidation profiling.
  • To discuss future directions for improving UGT-focused HTS.

Main Methods:

  • Review of existing literature on UGT assays and high-throughput screening methodologies.
  • Analysis of challenges associated with UGT enzyme characteristics (stability, expression, affinity, specificity) in HTS.
  • Examination of current HTS technologies and their application in drug glucuronidation studies.

Main Results:

  • HTS is a powerful tool for discovering UGT substrates and inhibitors, but faces significant challenges.
  • Difficulties include UGT enzyme instability, low expression, broad substrate specificity, and limited availability of purified isoforms.
  • Despite challenges, advancements in HTS technologies are improving drug glucuronidation profiling.

Conclusions:

  • Reliable UGT assays are essential for assessing isoform specificity and discovering novel substrates/inhibitors.
  • Overcoming HTS limitations is critical for advancing the study of UGTs and their clinical implications.
  • Future research should focus on developing more robust and informative HTS assays for UGTs.